Riluzole Zentiva (Riluzole 50 mg)
Generic glutamate release inhibitor for the treatment of amyotrophic lateral sclerosis (ALS)
Quick Facts About Riluzole Zentiva
Key Takeaways About Riluzole Zentiva
- Generic equivalent of Rilutek: Riluzole Zentiva contains the same active substance (riluzole 50 mg) and is bioequivalent to the originator product, with the same expected efficacy and safety profile
- Treats ALS: Riluzole is the first medicine ever approved specifically for amyotrophic lateral sclerosis (ALS) and remains a cornerstone of disease-modifying therapy worldwide
- Extends survival: Pivotal clinical trials show riluzole extends survival by approximately 2–3 months and may delay the need for tracheostomy or mechanical ventilation, particularly when initiated early
- Liver monitoring is essential: Regular blood tests to check liver function (ALT/AST) are required, especially during the first year of treatment
- Simple twice-daily dosing: One 50 mg tablet taken twice daily, every 12 hours, swallowed whole with water
- Tell your doctor about fever: Riluzole can lower white blood cell counts; report any unexplained fever immediately as it may indicate neutropenia
What Is Riluzole Zentiva and What Is It Used For?
Riluzole Zentiva is a generic prescription medicine used to treat amyotrophic lateral sclerosis (ALS), also known as motor neuron disease or Lou Gehrig's disease. Each film-coated tablet contains 50 mg of riluzole, which works by reducing the release of glutamate in the brain and spinal cord, helping to slow the destruction of motor neurons that control voluntary movement.
Riluzole Zentiva is a generic version of the originator product Rilutek, manufactured by the international pharmaceutical company Zentiva. As a generic medicine, it contains the same active ingredient in the same strength (50 mg of riluzole), is presented in the same dosage form (film-coated oral tablet), and is taken in the same way as the brand-name product. To receive marketing authorisation, generic medicines such as Riluzole Zentiva must demonstrate bioequivalence to the originator – meaning the active substance is delivered to the body in essentially the same way and at the same rate, producing the same therapeutic effect. Generic versions therefore offer the same clinical benefit, often at a lower cost to healthcare systems and patients.
The condition that Riluzole Zentiva is designed to treat – amyotrophic lateral sclerosis (ALS) – is a progressive neurodegenerative disease that affects the motor neurons. These specialised nerve cells transmit instructions from the brain and spinal cord to the muscles, enabling voluntary movement. As ALS progresses, motor neurons gradually deteriorate and die, causing muscles to weaken, atrophy and eventually become paralysed. Patients typically lose the ability to move, speak, swallow and ultimately breathe. The global incidence of ALS is approximately 2 per 100,000 person-years, with most cases occurring between the ages of 40 and 70.
The active substance in Riluzole Zentiva, riluzole, is a benzothiazole compound that acts on the central nervous system. Riluzole was the first drug approved specifically for ALS, receiving approval from the U.S. Food and Drug Administration (FDA) in 1995 and from the European Medicines Agency (EMA) shortly thereafter. It remains one of only a small number of pharmacological treatments available for this devastating condition, and it is included on the World Health Organization's Model List of Essential Medicines.
The primary mechanism of action involves inhibiting the release of glutamate, the principal excitatory neurotransmitter in the central nervous system. In ALS, excessive glutamate activity is believed to cause excitotoxic damage to motor neurons. By blocking glutamate release from presynaptic nerve terminals and interfering with voltage-dependent sodium channels, riluzole helps protect motor neurons from this type of damage. Riluzole may also have neuroprotective effects through other pathways, including interference with intracellular signalling that occurs after glutamate binds to its receptors and modulation of calcium influx into nerve cells.
It is important to understand that riluzole – whether taken as Riluzole Zentiva or as the originator Rilutek – does not cure ALS and does not reverse damage that has already occurred to motor neurons. However, two pivotal randomised controlled trials published in the 1990s and confirmed by subsequent meta-analyses (including a Cochrane systematic review) demonstrated that riluzole extends survival by approximately 2–3 months and delays the need for mechanical ventilation. Real-world evidence published over the past decade suggests that the benefit may be even greater when treatment is initiated early in the disease course and continued long-term, making timely diagnosis and treatment initiation particularly important.
Glutamate is the most abundant excitatory neurotransmitter in the central nervous system and plays essential roles in normal brain function, including learning and memory. However, when glutamate accumulates to excessive levels – as appears to occur in ALS – it overstimulates neurons, leading to a cascade of events that ultimately causes cell death. This process, known as excitotoxicity, is considered one of the key pathological mechanisms in ALS. By reducing glutamate release, riluzole helps mitigate this destructive process and provides modest neuroprotection.
In addition to ALS, the use of riluzole is being investigated in other conditions in which glutamate excitotoxicity may play a role, including spinocerebellar ataxia, certain forms of obsessive-compulsive disorder and treatment-resistant depression. However, these uses are off-label and experimental, and Riluzole Zentiva is not approved for these indications. Patients should only use Riluzole Zentiva for the indication and dose prescribed by their physician.
What Should You Know Before Taking Riluzole Zentiva?
Before starting Riluzole Zentiva, your doctor must evaluate your liver function, current medications and overall health status. Riluzole is contraindicated in patients with liver disease or elevated transaminases, during pregnancy and breastfeeding, and in those with known hypersensitivity to riluzole or its excipients.
Taking any medication requires careful consideration of potential risks and benefits. Because riluzole is metabolised primarily by the liver and can cause hepatotoxicity, a thorough medical evaluation is necessary before starting treatment. Your prescribing physician will consider your complete medical history, current medications and laboratory results to determine whether Riluzole Zentiva is appropriate for you. Even if you have previously taken Rilutek or another riluzole product, your doctor should review your status before switching to or continuing with the generic version.
Contraindications
You should not take Riluzole Zentiva if any of the following apply to you:
- Allergy to riluzole or any other ingredient: If you have ever had a hypersensitivity reaction to riluzole or to any of the excipients listed in the ingredients section, you must not take this medicine. Allergic reactions can range from mild skin rash to severe anaphylaxis
- Liver disease: If you have an existing liver condition (such as chronic hepatitis or cirrhosis) or if blood tests show elevated levels of liver enzymes (transaminases) above the recommended threshold, riluzole must not be used as it can worsen liver function
- Pregnancy: Riluzole Zentiva is contraindicated during pregnancy due to insufficient safety data and animal evidence of potential reproductive toxicity
- Breastfeeding: Riluzole is contraindicated in breastfeeding women, as it is unknown whether the active substance passes into breast milk and the risk to the nursing infant cannot be excluded
Warnings and Precautions
Speak with your doctor before taking Riluzole Zentiva if any of the following situations apply to you. These warnings are not absolute contraindications, but they require careful evaluation and possibly closer monitoring during treatment.
- Liver problems: If you notice yellowing of the skin or whites of the eyes (jaundice), widespread itching, dark urine, pale stools, persistent nausea or vomiting, contact your doctor immediately, as these may be signs of liver damage (hepatitis). Your doctor will perform regular blood tests to monitor liver function throughout treatment
- Kidney impairment: If your kidneys are not working properly, inform your doctor. While riluzole is primarily eliminated through hepatic metabolism, severe renal impairment may still require closer monitoring
- Unexplained fever: Report any fever to your doctor promptly. Riluzole can reduce the number of white blood cells (neutropenia), which can increase your risk of serious infection. A blood test may be needed to check your white blood cell count
- Cough or breathing difficulties: Report any new or worsening cough or shortness of breath, as these may be early signs of interstitial lung disease, a rare but potentially serious complication of riluzole therapy
- Pre-existing pancreatic disease: Cases of pancreatitis have been reported. If you have a history of pancreatic disease, this should be discussed with your doctor
Your doctor should check your liver enzymes (ALT/AST) before starting treatment, monthly for the first 3 months, every 3 months for the rest of the first year, and periodically thereafter. If ALT levels rise above 5 times the upper limit of normal, treatment should be stopped. Tell your doctor immediately if you develop signs of liver problems such as jaundice, dark urine, unexplained nausea or vomiting.
Pregnancy and Breastfeeding
You must not take Riluzole Zentiva if you are pregnant, think you may be pregnant, or are breastfeeding. There is insufficient data on the use of riluzole in pregnant women, and animal studies have demonstrated potential reproductive toxicity. If you are a woman of childbearing potential, discuss appropriate contraception with your doctor before starting treatment. Effective contraception should be used throughout treatment.
It is not known whether riluzole passes into human breast milk. Given the potential risks to the nursing infant, breastfeeding should be discontinued before starting riluzole therapy. If you are planning to become pregnant or discover that you are pregnant during treatment, contact your doctor immediately to discuss the best course of action. Treatment should not be discontinued abruptly without medical advice, as this may affect disease management.
Children and Adolescents
Riluzole Zentiva is not recommended for patients under 18 years of age. There are insufficient clinical data on the safety and efficacy of riluzole in children and adolescents with ALS or other conditions. ALS is exceedingly rare in this age group, and alternative diagnoses (such as juvenile-onset spinal muscular atrophy or other paediatric motor neuron disorders) should be carefully considered. If treatment of a paediatric patient with riluzole is being considered, this should only occur under specialist supervision with informed consent.
Driving and Operating Machinery
You may drive and use machinery while taking Riluzole Zentiva, provided you do not experience dizziness or light-headedness. These are known side effects of riluzole, particularly during the first weeks of treatment, and if they occur, you should avoid driving or operating dangerous machinery until the symptoms resolve. It is also important to note that ALS itself can impair motor function and may affect your ability to drive safely, regardless of medication. Your healthcare team can advise on driving safety as your condition evolves.
Switching Between Brand and Generic
If you are switching from the originator brand Rilutek to Riluzole Zentiva (or vice versa), no dose adjustment is needed because the products are bioequivalent. However, you should inform your doctor of any switch so that they can monitor for any unexpected changes in tolerability. Some patients may notice differences in tablet appearance (size, colour, markings) or excipients (inactive ingredients), but the active substance and clinical effect remain the same.
How Does Riluzole Zentiva Interact with Other Drugs?
Riluzole is primarily metabolised by the liver enzyme CYP1A2. Drugs that inhibit CYP1A2 (such as fluvoxamine and ciprofloxacin) can significantly increase riluzole blood levels, while CYP1A2 inducers (such as rifampicin, omeprazole and cigarette smoking) can decrease its effectiveness. Always inform your doctor about all medicines, supplements and lifestyle factors before starting Riluzole Zentiva.
Drug interactions are an important consideration with any medication. Riluzole is extensively metabolised in the liver, primarily by the cytochrome P450 enzyme CYP1A2, with minor contributions from CYP3A4 and other enzymes. Because of this metabolic pathway, several classes of drugs can affect riluzole blood concentrations, potentially increasing the risk of side effects (when levels rise) or reducing the drug's effectiveness (when levels fall).
It is essential to tell your doctor or pharmacist about all medicines you are currently taking, have recently taken, or might take. This includes prescription drugs, over-the-counter medications, herbal supplements, and vitamins. Your doctor can then assess whether any adjustments to your treatment plan are needed. Lifestyle factors, particularly cigarette smoking and dietary habits, can also influence CYP1A2 activity and should be discussed.
| Interacting Drug | Effect | Severity | Recommendation |
|---|---|---|---|
| Fluvoxamine (CYP1A2 inhibitor) | Increases riluzole levels up to 5-fold | Major | Avoid combination; use alternative antidepressant |
| Ciprofloxacin (CYP1A2 inhibitor) | Significantly increases riluzole levels | Major | Use alternative antibiotic if possible |
| Enoxacin (CYP1A2 inhibitor) | Substantially increases riluzole exposure | Major | Avoid combination; choose alternative antibiotic |
| Rifampicin (CYP1A2 inducer) | Decreases riluzole levels; may reduce efficacy | Moderate | Monitor closely; assess clinical response |
| Omeprazole (CYP1A2 inducer) | May decrease riluzole levels | Moderate | Consider alternative proton pump inhibitor |
| Theophylline (CYP1A2 substrate) | Competitive metabolism; may alter levels of both drugs | Moderate | Monitor theophylline levels closely |
| Caffeine (CYP1A2 substrate) | Mild competitive metabolism | Minor | Normal intake acceptable; avoid excessive consumption |
| Hepatotoxic drugs | Increased risk of liver damage | Major | Avoid if possible; increase liver monitoring frequency |
| Cigarette smoking | Induces CYP1A2; may decrease riluzole levels | Moderate | Inform doctor of smoking status; monitor response |
| Alcohol | Increased hepatotoxicity risk; worsens dizziness/drowsiness | Moderate | Limit or avoid alcohol consumption |
Major Interactions
The most clinically significant interaction is with fluvoxamine, a potent CYP1A2 inhibitor used as an antidepressant. Co-administration can increase riluzole plasma concentrations by up to 5-fold, dramatically raising the risk of hepatotoxicity, neutropenia and other adverse effects. This combination should be avoided entirely; if antidepressant therapy is required, an alternative agent that does not strongly inhibit CYP1A2 should be selected. Similarly, ciprofloxacin and enoxacin, commonly prescribed fluoroquinolone antibiotics, are strong CYP1A2 inhibitors that can substantially raise riluzole levels.
Other potent CYP1A2 inhibitors to be aware of include ticlopidine, methoxsalen, and some herbal preparations such as caffeine-containing supplements consumed in very high doses. Concomitant use of other hepatotoxic medications – such as certain antibiotics (e.g. erythromycin, isoniazid), antifungals (ketoconazole, itraconazole), anticonvulsants (phenytoin, valproic acid), or high-dose acetaminophen (paracetamol) – can compound the liver risks associated with riluzole and should be approached with caution. If unavoidable, more frequent liver monitoring is required.
Minor Interactions
Mild CYP1A2 inducers and inhibitors may have modest effects on riluzole blood levels that are generally not clinically significant but should still be considered. Caffeine is a CYP1A2 substrate, and while normal dietary caffeine intake is unlikely to cause problems, very high caffeine consumption could theoretically compete with riluzole metabolism. Charcoal-grilled foods contain polycyclic aromatic hydrocarbons that induce CYP1A2 and may slightly reduce riluzole levels if consumed regularly in large quantities. These dietary factors do not normally require avoidance but illustrate the breadth of CYP1A2 modulators.
Cruciferous vegetables (such as broccoli, cabbage and Brussels sprouts) also induce CYP1A2 to a modest degree; normal dietary intake is unlikely to be clinically significant. Grapefruit juice, which strongly inhibits CYP3A4, is unlikely to have a major impact on riluzole given the dominant role of CYP1A2 in its metabolism.
What Is the Correct Dosage of Riluzole Zentiva?
The recommended dose of Riluzole Zentiva is one 50 mg tablet twice daily (total 100 mg per day), taken every 12 hours at the same times each day, such as morning and evening. Swallow the tablets whole with water, with or without food. Do not adjust the dose without consulting your doctor.
Always take Riluzole Zentiva exactly as your doctor has prescribed. If you are unsure about any aspect of your dosing, consult your doctor or pharmacist. The standard dosing regimen is straightforward and does not typically require adjustment based on body weight, age or the severity of ALS symptoms. Consistency in timing is important to maintain stable blood levels of the drug throughout the day and to optimise therapeutic effect.
Adults
Standard Adult Dosage
50 mg (one tablet) twice daily, taken approximately every 12 hours. The total daily dose is 100 mg. Take the tablets at consistent times each day – for example, one tablet in the morning and one in the evening. Swallow the tablet whole with water. Riluzole Zentiva can be taken with or without food, though taking it at the same times helps ensure consistent drug levels and supports adherence.
Clinical trials evaluated various doses of riluzole, ranging from 50 mg to 200 mg daily. The 100 mg daily dose (50 mg twice daily) was established as the optimal balance between efficacy and tolerability. Higher doses did not provide additional survival benefit but were associated with a significantly increased risk of adverse effects, particularly liver toxicity and gastrointestinal symptoms. Therefore, the standard 100 mg per day dose should not be exceeded.
Children
Paediatric Use
Not recommended. Riluzole Zentiva is not approved for use in patients under 18 years of age. Insufficient clinical data exist regarding the safety and efficacy of riluzole in paediatric populations. ALS is exceedingly rare in children, and use in this population should only be considered under exceptional circumstances with specialist supervision and informed consent.
Elderly
Elderly Patients (65 years and older)
No dose adjustment is generally required for elderly patients. However, because older individuals are more likely to have reduced hepatic and renal function, closer monitoring – particularly of liver enzymes – may be prudent. Pharmacokinetic differences in elderly patients are typically modest. Your doctor will determine the most appropriate monitoring schedule based on your individual health status, comorbidities and concomitant medications.
Patients with Kidney Impairment
Renal Impairment
The pharmacokinetics of riluzole have not been adequately studied in patients with renal impairment. Because riluzole is primarily metabolised by the liver, severe renal dysfunction is unlikely to significantly alter drug clearance. However, caution and individualised monitoring are advised, especially in advanced renal failure.
Patients with Liver Impairment
Hepatic Impairment
Contraindicated. Riluzole Zentiva must not be used in patients with hepatic impairment or those with elevated baseline transaminases (typically defined as more than 3 times the upper limit of normal). The risk of further liver damage outweighs the potential benefit in such patients.
Missed Dose
If you forget to take a dose of Riluzole Zentiva, skip the missed dose and take the next dose at your regular scheduled time. Do not take a double dose to compensate for the forgotten tablet. Taking two doses too close together can increase the risk of side effects, particularly nausea, dizziness and elevated liver enzymes. If you frequently forget doses, consider setting a daily alarm, using a pill organiser or asking a caregiver for support to help you remember. Adherence is important because consistent blood levels of riluzole are needed to achieve the disease-modifying benefit.
Overdose
If you have taken more tablets than prescribed, contact your doctor or go to the nearest emergency department immediately. Symptoms of overdose may include nausea, vomiting, severe drowsiness, confusion, dizziness, tachycardia and potentially serious liver damage. Encephalopathy and methaemoglobinaemia have been reported in rare overdose cases. There is no specific antidote for riluzole overdose; treatment is supportive and symptomatic and may include activated charcoal, intravenous fluids and monitoring of liver function. Bring the medication packaging with you to help healthcare providers understand what you have taken.
| Patient Group | Dose | Frequency | Notes |
|---|---|---|---|
| Adults | 50 mg | Twice daily (every 12 hours) | Total daily dose: 100 mg |
| Elderly (65+) | 50 mg | Twice daily (every 12 hours) | No routine adjustment; monitor liver function closely |
| Children (<18 years) | Not recommended | N/A | Insufficient safety and efficacy data |
| Renal impairment | 50 mg | Twice daily | Use with caution; individualised monitoring |
| Hepatic impairment | Contraindicated | N/A | Do not use in liver disease or elevated ALT/AST |
| Pregnant or breastfeeding | Contraindicated | N/A | Insufficient safety data; use effective contraception |
What Are the Side Effects of Riluzole Zentiva?
The most common side effects of Riluzole Zentiva include tiredness (asthenia), nausea and elevated liver enzymes. More serious but less common side effects include hepatitis (liver inflammation), neutropenia (low white blood cells) and interstitial lung disease. Report any unexplained fever, jaundice or breathing difficulties to your doctor immediately.
Like all medicines, Riluzole Zentiva can cause side effects, although not everybody experiences them. The side-effect profile of Riluzole Zentiva mirrors that of the originator product Rilutek, because both contain the same active substance. Most side effects are mild to moderate and may improve as your body adjusts to the medication. However, some side effects can be serious and require immediate medical attention. Understanding what to watch for can help you work with your doctor to manage your treatment safely.
- Fever: Riluzole can lower your white blood cell count. Your doctor may need to check your blood to rule out neutropenia, which increases infection risk
- Yellowing of the skin or eyes (jaundice), whole-body itching, dark urine, pale stools, persistent nausea or vomiting: These may be signs of liver damage (hepatitis). Regular blood tests are essential to detect this early
- Cough or difficulty breathing: These may indicate interstitial lung disease, a rare but potentially serious complication
- Severe abdominal pain: Could indicate pancreatitis
- Severe skin rash, swelling of the face or throat, or difficulty breathing: Signs of a serious allergic reaction requiring emergency care
Very Common Side Effects
- Tiredness (asthenia/fatigue)
- Nausea
- Elevated blood levels of liver enzymes (transaminases)
Common Side Effects
- Dizziness
- Drowsiness (somnolence)
- Headache
- Tingling in the mouth (oral paraesthesia)
- Increased heart rate (tachycardia)
- Abdominal pain
- Vomiting
- Diarrhoea
- Pain
Uncommon Side Effects
- Anaemia (low red blood cell count)
- Allergic reactions (hypersensitivity)
- Pancreatitis (inflammation of the pancreas)
Reported Side Effects
- Skin rash
- Hepatitis (liver inflammation)
- Interstitial lung disease
- Neutropenia (low white blood cell count)
- Angioedema (rapid swelling of skin/mucosa)
- Anaphylactoid reactions
Understanding Liver-Related Side Effects
Elevated transaminases (liver enzymes) are one of the most common side effects of riluzole and can occur in more than 10% of patients. In most cases, these elevations are mild, asymptomatic and resolve either spontaneously or after dose reduction. However, in some patients, the elevation can be significant enough to indicate liver damage (hepatotoxicity). The mechanism is thought to involve direct hepatocellular injury, with most cases occurring within the first 3–6 months of treatment.
The recommended monitoring schedule – monthly for the first three months, then every three months during the first year, and periodically thereafter – is designed to detect liver problems early, before they become clinically significant. If your ALT level rises above 5 times the upper limit of normal, your doctor will likely discontinue Riluzole Zentiva. Patients with pre-existing liver conditions, those taking other hepatotoxic medications, those who consume alcohol regularly, or those with viral hepatitis are at higher risk and should be monitored more frequently. In most cases, transaminase elevations normalise after stopping the medicine.
Managing Common Side Effects
Nausea is one of the most frequently reported side effects and is usually mild. Taking Riluzole Zentiva with food may help reduce nausea, although this is not strictly required from a pharmacokinetic perspective. If nausea is persistent and bothersome, your doctor may recommend anti-nausea medication. Splitting your meals into smaller portions and avoiding rich or fatty foods around the time of dosing can also help.
Fatigue (asthenia) is another very common effect and can sometimes be difficult to distinguish from the fatigue caused by ALS itself. Maintaining a regular sleep schedule, prioritising activities and engaging in gentle physical activity as tolerated may help manage this symptom. Pacing strategies and energy-conservation techniques taught by occupational therapists can be valuable.
Dizziness and drowsiness can affect your ability to drive or operate machinery safely. These effects are usually transient, occurring most commonly during the first few weeks of treatment. If they persist, discuss this with your doctor. Oral tingling (paraesthesia) is a distinctive side effect of riluzole and is generally harmless and temporary, though it may be uncomfortable. It typically occurs shortly after taking the tablet and resolves within minutes.
Serious Adverse Effects: When to Seek Emergency Care
Although serious adverse effects are uncommon with riluzole, you should seek emergency medical care if you experience any of the following: severe difficulty breathing, swelling of the face, lips, tongue or throat, severe widespread skin rash with blistering, sudden severe abdominal pain (which could indicate pancreatitis), or signs of severe infection such as high fever with chills (which could indicate neutropenic sepsis). These symptoms may indicate life-threatening reactions that require immediate intervention.
If you experience any side effects – whether listed here or not – talk to your doctor, pharmacist or nurse. You can also report side effects directly to your national medicines agency (for example, the FDA MedWatch program in the United States, the Yellow Card Scheme in the United Kingdom, the EudraVigilance system via national authorities in the European Union, or equivalent pharmacovigilance schemes in other countries). By reporting side effects, you help provide important safety information about medicines, including generic versions such as Riluzole Zentiva.
How Should You Store Riluzole Zentiva?
Store Riluzole Zentiva at room temperature (below 30°C), out of the reach and sight of children. No special storage conditions are required. Keep the tablets in their original blister packaging until you are ready to take them. Do not use after the expiry date printed on the packaging. Do not dispose of medicines via wastewater or household waste – ask your pharmacist for proper disposal methods.
Proper storage of medications is important to ensure they remain effective and safe to use. Riluzole Zentiva does not require any special storage conditions – it should be kept at normal room temperature, away from excessive heat, moisture and direct sunlight. The bathroom is generally not an ideal storage location due to humidity. A cool, dry kitchen cupboard or bedroom drawer is more suitable, provided it is out of reach of children.
Keep the tablets in their original blister packaging until you are ready to take them. The blister provides protection from light and moisture and helps ensure that each tablet remains stable until use. Do not transfer the tablets to other containers without medical or pharmacist advice, as this could affect drug stability.
Always check the expiry date on the carton and blister pack before taking a tablet. The expiry date refers to the last day of the month indicated. Do not use Riluzole Zentiva after this date, as the drug's potency and safety cannot be guaranteed beyond the expiration period.
Keep this medicine out of the sight and reach of children. Accidental ingestion by a child can be dangerous. If a child accidentally takes Riluzole Zentiva, seek medical attention immediately and bring the packaging with you so that healthcare providers can identify the medicine.
Unused or expired medicines should not be thrown in regular household waste or flushed down the toilet. Instead, return them to your pharmacy for safe disposal. Many countries have take-back schemes for unused medicines. These measures help protect the environment from pharmaceutical contamination and prevent accidental ingestion by others.
What Does Riluzole Zentiva Contain?
Each Riluzole Zentiva tablet contains 50 mg of the active substance riluzole. The inactive ingredients (excipients) typically include calcium hydrogen phosphate (anhydrous), microcrystalline cellulose, anhydrous colloidal silica, magnesium stearate and croscarmellose sodium in the tablet core, with hypromellose, macrogol and titanium dioxide (E171) in the film coating. Always refer to the patient information leaflet supplied with your specific pack for the complete excipient list.
Understanding the composition of your medicine is important, particularly if you have known allergies or sensitivities to specific excipients. The active ingredient, riluzole, is a benzothiazole compound with the chemical name 2-amino-6-(trifluoromethoxy)benzothiazole. Each film-coated tablet of Riluzole Zentiva contains exactly 50 mg of riluzole. Although Riluzole Zentiva is bioequivalent to the originator product Rilutek, the inactive ingredients in generic medicines may differ slightly between manufacturers; the patient information leaflet supplied in your pack provides the definitive excipient list.
Active Ingredient
Riluzole 50 mg – a glutamate release inhibitor with neuroprotective properties. Riluzole has a molecular weight of 234.2 g/mol and is practically insoluble in water but soluble in dimethylformamide and methanol. The molecule was originally developed by Rhône-Poulenc Rorer in the 1990s and is now produced as a generic compound by multiple manufacturers, including Zentiva.
Inactive Ingredients (Excipients)
The inactive ingredients serve various pharmaceutical functions to ensure tablet stability, appearance, manufacturability and consistent drug release. Typical excipients in Riluzole Zentiva 50 mg film-coated tablets include:
- Tablet core: calcium hydrogen phosphate (anhydrous) as a filler/diluent; microcrystalline cellulose as a binder; anhydrous colloidal silica as a glidant; magnesium stearate as a lubricant; croscarmellose sodium as a disintegrant
- Film coating: hypromellose as a film-forming agent; macrogol (polyethylene glycol) as a plasticiser; titanium dioxide (E171) as an opacifier and whitening agent
If you have known intolerance to any of these excipients, discuss this with your doctor or pharmacist before starting treatment. While serious reactions to excipients are rare, sensitivities can occur. Some excipients are common across many tablet medicines, so a switch to an alternative formulation may not always be possible.
Appearance and Packaging
Riluzole Zentiva 50 mg film-coated tablets are typically white to off-white, capsule-shaped or round film-coated tablets. The exact appearance, including any embossing or scoring, depends on the manufacturing batch and the local market in which the product is supplied. The medicine is generally supplied in blister strips packaged in cartons of 56 tablets (corresponding to a 28-day supply at the standard dose), although other pack sizes may be available depending on the country.
Riluzole Zentiva 50 mg film-coated tablets contain less than 1 mmol (23 mg) of sodium per tablet, which means they are essentially sodium-free. This is relevant for patients on sodium-restricted diets, such as those with heart failure or kidney disease.
A generic medicine contains the same active substance, in the same dose and dosage form, as the originator (brand-name) product. Before approval, generic medicines must demonstrate bioequivalence to the originator through pharmacokinetic studies, meaning the drug enters the bloodstream at essentially the same rate and to the same extent. This ensures the same therapeutic effect. Generic medicines may differ in tablet size, shape, colour, markings or excipients (inactive ingredients), but the clinical performance is equivalent. Generics typically become available after the original patent expires and offer significant cost savings to patients and healthcare systems while maintaining quality and efficacy.
Frequently Asked Questions About Riluzole Zentiva
Riluzole Zentiva is a generic prescription medicine used to treat amyotrophic lateral sclerosis (ALS), also known as motor neuron disease or Lou Gehrig's disease. It contains 50 mg of riluzole – the same active substance as the originator brand Rilutek – and works by reducing the release of glutamate, a chemical messenger in the brain that can damage nerve cells when present in excess. Clinical trials show riluzole extends survival by approximately 2–3 months and may delay the need for mechanical ventilation. It does not cure ALS but helps slow disease progression.
Yes. Riluzole Zentiva is a generic equivalent of the originator brand Rilutek. Both contain the same active ingredient (50 mg of riluzole) in the same dosage form (film-coated tablet). Generic medicines must demonstrate bioequivalence to the originator before they can be marketed, meaning they deliver the active substance to the body in essentially the same way and at the same rate. The expected efficacy and safety profile are therefore the same. Switching between the brand and generic does not require dose adjustment, although you should always inform your doctor about any change in medication.
Riluzole works primarily by inhibiting the release of glutamate from presynaptic nerve terminals in the central nervous system. In ALS, motor neurons are damaged partly due to excessive glutamate activity (a process called excitotoxicity). By reducing glutamate release and blocking voltage-dependent sodium channels, riluzole helps protect remaining motor neurons from further damage. It also interferes with intracellular signalling pathways that contribute to neuronal death. The result is a modest slowing of disease progression and a small but meaningful extension of survival.
Regular blood tests are necessary because riluzole can affect your liver function. Elevated liver enzymes (transaminases) are one of the most common side effects, occurring in more than 10% of patients. Your doctor will check your liver enzymes before starting treatment, monthly for the first 3 months, every 3 months during the rest of the first year and periodically thereafter. Additionally, riluzole can sometimes lower your white blood cell count (neutropenia), so blood tests help detect this early. If significant liver enzyme elevations are detected, your doctor may need to stop the medication temporarily or permanently.
While there is no absolute prohibition against alcohol use with riluzole, it is generally advisable to limit or avoid alcohol consumption. Both riluzole and alcohol are metabolised by the liver, and combining them may increase the risk of hepatotoxicity (liver damage). Alcohol can also worsen common side effects such as dizziness, drowsiness and nausea. Discuss your alcohol consumption with your doctor, who can provide personalised advice based on your liver function test results, overall health and other medications you are taking.
No. Riluzole Zentiva cannot cure ALS. Currently, there is no cure for amyotrophic lateral sclerosis. Riluzole is a disease-modifying treatment that has been shown to slow disease progression and extend survival by approximately 2–3 months on average. The benefit appears greatest when treatment is started early in the disease course. Riluzole is most effective as part of a comprehensive management approach that includes physical therapy, occupational therapy, speech therapy, nutritional support, respiratory care and multidisciplinary team care delivered in a specialist ALS clinic.
Difficulty swallowing (dysphagia) is a common symptom of ALS that can make taking tablets challenging. If you have trouble swallowing Riluzole Zentiva tablets, talk to your doctor or pharmacist. In some countries, an oral suspension formulation of riluzole is available, which may be easier to swallow. Your doctor or pharmacist may also be able to advise on whether the tablets can be crushed or dissolved with food or liquid. Never modify your medication without consulting your healthcare team first, as this can affect how the drug is absorbed and tolerated.
Yes, switching between Rilutek and Riluzole Zentiva is generally straightforward because both products are bioequivalent and contain the same active ingredient (50 mg of riluzole) in the same dosage form. The dose and dosing schedule do not change. You should always inform your doctor and pharmacist about any switch so that they can update your records and monitor for any unexpected differences in tolerability. Some patients notice differences in tablet appearance, but the clinical effect remains the same.
References
- Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. New England Journal of Medicine. 1994;330(9):585-591. doi:10.1056/NEJM199403033300901
- Lacomblez L, Bensimon G, Leigh PN, et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. The Lancet. 1996;347(9013):1425-1431. doi:10.1016/S0140-6736(96)91680-3
- Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database of Systematic Reviews. 2012;(3):CD001447. doi:10.1002/14651858.CD001447.pub3
- European Medicines Agency (EMA). Rilutek – Summary of Product Characteristics. Last updated 2023.
- European Medicines Agency (EMA). Generic and Hybrid Medicines – Scientific Guidelines.
- U.S. Food and Drug Administration (FDA). Riluzole – Prescribing Information. Revised 2023.
- National Institute for Health and Care Excellence (NICE). Motor neurone disease: assessment and management. NICE guideline [NG42]. Updated 2024.
- Andersen PM, Abrahams S, Borasio GD, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS). European Journal of Neurology. 2012;19(3):360-375.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List, 2023.
- Bellingham MC. A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis. CNS Neuroscience & Therapeutics. 2011;17(1):4-31.
- Andrews JA, Jackson CE, Heiman-Patterson TD, et al. Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2020;21(7-8):509-518.
- British National Formulary (BNF). Riluzole monograph. Joint Formulary Committee. London: BMJ Group and Pharmaceutical Press, 2024.
Editorial Team
Medical Content
iMedic Medical Editorial Team
Specialists in neurology and clinical pharmacology with extensive experience in neurodegenerative disease management and drug information.
Medical Review
iMedic Medical Review Board
Independent panel of medical experts who review all content according to international guidelines (EMA, FDA, NICE, AAN).
This article was written based on official prescribing information from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), supplemented by peer-reviewed clinical trial data, international treatment guidelines and the British National Formulary. All content follows the GRADE evidence framework and is reviewed regularly to reflect the latest clinical evidence.
Last medical review: | Next scheduled review: